⌕
Alvotech · ALVO · Nasdaq
Tenet 41 · Weak
Compare
$4.37−0.79%At closeTenet 41 · Weak
$4.37−0.04 (−0.79%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Alvotech (ALVO) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ALVO's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 19:42 ET
Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript

Alvotech ( ALVO ) UBS Global Biopharma Conference 2026 November 17, 2026 9:00 AM EST Company Participants Robert Wessman - Founder & Executive Chairman Balaji Prasad - Chief Strategy Officer Conference Call Participants …

ALVO −0.8% todayRead at source ↗
● MarketBeatNov 12, 2026 · 11:16 ET
What Alvotech (ALVO) Said on Its Q3 Earnings Call

Alvotech NASDAQ: ALVO expects its full-year revenue and adjusted earnings to land near the lower end of its guidance range, as the biosimilar maker works to increase deliveries following a manufacturing slowdown.…

ALVO −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 11, 2026 · 18:56 ET
Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates

Alvotech (ALVO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.…

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireNov 11, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update

REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicine…

ALVO −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 11:01 ET
Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know

Alvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

ALVO −0.8% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 05:16 ET
Alvotech: The Market Is Still Pricing The Broken Factory

Alvotech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward decisions this quarter. ALVO's guidance implies a significant second-half …

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Alvotech to Present at Upcoming Investor Conferences in November

REYKJAVIK,  ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced t…

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

REYKJAVIK,  ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, t…

ALVO −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 21, 2026 · 07:45 ET
New Strong Sell Stocks for October 21st

ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.…

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireOct 20, 2026 · 04:30 ETCOMPANY'S OWN WORDS
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio…

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireOct 14, 2026 · 04:30 ETCOMPANY'S OWN WORDS
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)…

ALVO −0.8% todayRead at source ↗
● Defense WorldOct 13, 2026 · 04:45 ET
Alvotech (NASDAQ:ALVO) Stock Has Consensus Target Price of $8.50 According to Brokerages

Shares of Alvotech (NASDAQ: ALVO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rate…

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership to increase Alvotech's global manufacturing capacity and support grow…

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireOct 5, 2026 · 04:00 ET
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech's biosimilar to Humira®

Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites…

ALVO −0.8% todayRead at source ↗
● Defense WorldSep 21, 2026 · 04:45 ET
Alvotech (NASDAQ:ALVO) Receives $8.50 Average Target Price from Brokerages

Alvotech (NASDAQ: ALVO - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rec…

ALVO −0.8% todayRead at source ↗
● Seeking AlphaSep 15, 2026 · 15:11 ET
Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

ALVO −0.8% todayRead at source ↗
● Defense WorldSep 15, 2026 · 03:18 ET
Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS)

Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength…

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireAug 31, 2026 · 04:30 ETCOMPANY'S OWN WORDS
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations

REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that…

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireAug 27, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Alvotech to present at upcoming investor conferences in September

REYKJAVIK,  ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced th…

ALVO −0.8% todayRead at source ↗
● BenzingaAug 24, 2026 · 10:22 ET
Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday

U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Monday.…

ALVO −0.8% todayRead at source ↗
● GlobeNewsWireAug 21, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, toda…

ALVO −0.8% todayRead at source ↗
● Seeking AlphaAug 20, 2026 · 14:21 ET
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts

Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues, now addressed, with B…

ALVO −0.8% todayRead at source ↗
● Seeking AlphaAug 20, 2026 · 11:51 ET
Alvotech (ALVO) Q2 2026 Earnings Call Transcript

Alvotech (ALVO) Q2 2026 Earnings Call Transcript…

ALVO −0.8% todayRead at source ↗
● MarketBeatAug 20, 2026 · 10:03 ET
Alvotech Q2 Earnings Call Highlights

Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue an…

ALVO −0.8% todayRead at source ↗
● Zacks Investment ResearchAug 19, 2026 · 18:46 ET
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates

Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.…

ALVO −0.8% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just ALVO · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.